• American West Metals Limited entered into binding agreement with Australian-based Taurus Mining Royalty Fund L.P.
• The royalty funding supports the advancement of the Storm Copper Project
• The investment from Taurus is a strong endorsement of the potential at Storm

Aston Bay Holdings (TSX.V: BAY) (OTCQB: ATBHF), a publicly traded mineral exploration company, and its joint venture partner, American West Metals Limited, are making significant plans to move forward on development of the Storm Copper Project, located in Nunavut, Canada. The plans follow the announcement that American West secured nondilutive financing from a leading royalty fund to support exploration and development at Storm (https://ibn.fm/L5Bn2).

According to the announcement, American West entered into a binding agreement with Australian-based Taurus Mining Royalty Fund L.P. The agreement calls for Taurus to provide up to $12.5 million under a royalty package for the Storm Copper Project. In return, Taurus receives a new 0.95% gross override royalty from all production at the project.

“We are very pleased to have secured royalty funding to support the advancement of the Storm Copper Project,” said Dave O’Neill, managing director of American West Metals. “The royalty financing provides American West with a substantial quantum of funds on terms that are considerably more attractive and less dilutionary than alternative equity funding.

“The investment from Taurus is a strong endorsement of the potential at Storm and recognizes the strong foundations for growth established by the exploration and resource delineation work conducted by American West to date,” O’Neill continued. “The company is now well positioned to accelerate the 2024 and 2025 work programs at Storm, with the 2024 summer drilling program now in full swing. This puts American West in a strong position to grow shareholder wealth as the demand outlook for copper reaches an all-time high.”

AmericanWest plans to use the funds to accelerate the Storm 2024 resource expansion and exploration programs. Funds will also be used to bring forward the logistics for the 2025 field activities and expedite the completion of environmental, social and governance (“ESG”); mining; and development studies. Aston Bay will receive 20% of the funding with no use-of-proceeds restriction.

“This is an excellent development for the Storm Project and Aston Bay,” said Thomas Ullrich, Aston Bay CEO. “The royalty financing provides significant funding and is structured to promote rapid advancement of the Storm Copper Project for our partner American West. At the same time, it provides a significant amount of nondilutive funds for Aston Bay to advance our other critical minerals and gold exploration projects in Nunavut and Virginia.”

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet or exceed industry standards and government codes and regulations.

Aston Bay is a publicly traded mineral exploration company exploring for high-grade critical and precious metal deposits in Nunavut, Canada, and the state of Virginia. The company is led by CEO Thomas Ullrich with exploration in Virginia directed by the company’s advisor, Don Taylor, the 2018 Thayer Lindsley Award winner for his discovery of the Taylor Pb-Zn-Ag Deposit in Arizona. The company is currently exploring the Storm Copper and Epworth Properties in Nunavut and the high-grade Buckingham Gold Vein in central Virginia. The company is also in advanced stages of negotiation on other lands with high-grade critical metals potential in North America.

For more information, visit the company’s website at https://AstonBayHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ATBHF are available in the company’s newsroom at https://ibn.fm/ATBHF

• Israel-headquartered SuperCom Ltd. has developed its PureSecurity Suite of secure identification and electronic monitoring products as an end-to-end solution for increasing public safety worldwide
• SuperCom recently announced it has received orders valued at over $3 million from European governments, to be delivered in Q3 of 2024
• In April, the company similarly announced over $5 million in new orders from European governments for the company’s EM solutions, showing that SuperCom’s products and services remain popular in the region

Security solutions innovator SuperCom (NASDAQ: SPCB) is a growing provider of electronic monitoring technologies for a variety of primarily governmental client needs. Applications include the supervision of individuals in criminal cases who have qualified for home-based detention as an alternative to incarceration, as well as rehabilitation and domestic violence prevention programs.

Most recently, the company has announced more than $3 million of orders from EU governments to serve the needs of correctional facilities and law enforcement agencies, adding to the $5 million of new European government orders the company announced in April.

“The new orders strengthen our position as a global leader in electronic monitoring solutions for public safety,” SuperCom President and CEO Ordan Trabelsi stated (https://ibn.fm/3biTe). “Our recent successes in securing substantial orders from European governments reflect our unwavering commitment to delivering exceptional results and our ability to meet the evolving needs of our clients. SuperCom remains dedicated to ensuring successful project execution and fostering lasting partnerships with governments worldwide.”

SuperCom provides traditional and digital identity solutions on an internationally. This year, its most recent contracts have been requisitioned to meet the needs of agencies in Europe. The company has also expressed a particular focus on serving public safety agency needs in the United States as well.

SuperCom’s end-to-end electronic monitoring solution is branded as PureSecurity Suite. It delivers state-of-the-art GPS tracking and monitoring technologies through a secure software platform.

The PureSecurity Suite provides real-time reporting as part of its communication functions. Needs that are served range from ensuring that home-detention orders are obeyed, to substance abuse rehabilitation conditions established as part of treatment.  In addition, real-time reporting can be of critical value when used for court-ordered EM tracking of domestic violence offenders.

SuperCom’s security solutions serve organizations in both the public and private sectors. The company also offers proprietary e-government platforms for traditional identification needs as well as biometrics enrollment, personalization, issuance and border control services.

The company’s e-government division announced its most recent contract acquisition in May when it landed a $1.8 million new project from a long-standing customer.

The company’s solutions also include a Safend’s Data Protection Suite as a software solution for protecting organizations from data leakage and theft. The suite product protects data-in-use, data-at-rest and data-in-motion without hampering workers’ productivity.

“Since 2018, SuperCom has secured over 50 new multi-year government projects,” Trabelsi stated in an April investor discussion about the company’s year-end financial report (https://ibn.fm/yqDoD). “Our strong growing reputation as a premium provider of electronic monitoring solutions and services enhanced our market position with each new customer win.”

The company’s announcement states the new European government contracts are expected to be delivered by the end of the third quarter this year.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• For the first time in Medicare’s history, more than half of all eligible people with Medicare are enrolled in private Medicare Advantage plans
• Enrollment in Medicare Advantage programs is projected to grow from 54% of the eligible population in 2024 to 60% by the end of the decade
• Astiva Health has developed one of the most diverse networks in Southern California and offers a selection of benefits tailored to the specialized needs of its members

According to a recent KFF report, a record number of people enrolled in private Medicare Advantage plans last year (https://ibn.fm/YEpRJ). That trend bodes well for Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan that is committed to reshaping personalized and comprehensive healthcare.

“For the first time in Medicare’s history, more than half of all eligible people with Medicare, or 30.8 million people in 2023, are enrolled in private Medicare Advantage plans,” reported the KFF article. “Medicare Advantage plans are offered by private health insurance companies that receive payments from the federal government to provide Medicare-covered services. People with Medicare have a choice between traditional Medicare (sometimes called fee-for-service Medicare or Original Medicare) and Medicare Advantage plans.

“The growth in Medicare Advantage enrollment is driven by a number of factors, including the Medicare payment system, which has served to attract and retain insurers and beneficiaries, rather than reduce Medicare spending,” the article continued. “Medicare Advantage enrollment has more than doubled since 2010 and is projected to grow from 54% of the eligible population in 2024 to 60% by the end of this decade.”

The article, titled “10 Reasons Why Medicare Advantage Enrollment is Growing and Why It Matters,” noted several reasons for the upward trend. First and foremost, “people with Medicare are drawn to Medicare Advantage for the extra benefits,” stated the article. Those benefits include reduced cost-sharing, dental coverage, gym memberships and debit cards for over-the-counter medical supplies that are not covered by traditional Medicare.

In addition, people with Medicare are drawn to Medicare Advantage plans that are marketed as “zero premium” products, the article pointed out. “Like traditional Medicare beneficiaries, Medicare Advantage enrollees are required to pay the Medicare Part B premium, but unlike beneficiaries in traditional Medicare, they typically do not pay a separate premium for additional coverage or for Part D prescription drug premium because Medicare Advantage rebate dollars cover these costs.”

Other reasons for increased enrollment in Medicare Advantage plans include premiums for Part D standalone prescription drug plans that supplement traditional Medicare are rising rapidly and people with Medicare are attracted to the financial protection that comes with an annual out-of-pocket limit that Medicare Advantage plans are required to provide. In addition to the financial benefits, people with Medicare are attracted to the simplicity and convenience of Medicare Advantage, which provides all coverage in one plan, eliminating the need to obtain a Medicare Part D plan and a Medigap plan.

Astiva Health is focused on being a leader in the Medicare Advantage space. The company is keenly aware of the uniqueness of its members and is dedicated to delivering quality care to each individual. With that in mind, the company has developed one of the most diverse networks in Southern California and offers a selection of benefits tailored to the specialized needs of its members.

“We believe that health is an essential key to living a good life,” the company states (https://ibn.fm/iyf5U). “We are making it our mission to help our members love life through community-based health plans focused on serving individual member needs, tailored comprehensive benefit packages to meet member’s personalized needs and best support our local, underserved member population, and a culturally responsive approach to healthcare offering multilingual solutions for customer service, marketing materials and educational materials. Our mission is to deliver an unparalleled level of quality care to our members and establish relationships that will last a lifetime.”

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

• Ohio’s Cuyahoga County established a green energy utility three years ago, and recently signed a 10-year contract with companies Distributed Energy Capital and Compass Energy Platform to manage the first-in-the-nation community power operation
• Distributed Energy Capital is a subsidiary of Correlate Energy Corp., a distributed energy solutions developer that works strategically with partners to help clients make the transition to green energy transition
• Key development milestones for the utility are expected by next year, with a focus on supporting economic growth in the Cleveland metro region under a renewable energy model
• The partnership for the distributed energy utility model is being addressed with other municipalities, exhibiting its potential for scalable growth
• The microgrid energy distribution market is experiencing growth at a CAGR of 18.5 percent during the next five years, demonstrating interest in its development

The microgrid energy distribution market is expected to grow at a CAGR of 18.5 percent during the next five years to a valuation of $87.8 billion dollars, according to analysts at MarketsandMarkets Research, reflecting a rising interest worldwide in reducing climate-altering pollution as well as the burgeoning need for energy to power an increasing array of computerized resources (https://ibn.fm/h7DiI).

The report notes technical and logistical hurdles to the interconnectivity of microgrids that present significant obstacles to the market’s expansion, but distributed energy solutions company Correlate Energy (OTCQB: CIPI) is driving scalability in the market with a new partnership between its subsidiary Distributed Energy Capital (“DEC”) and clean energy development innovator Compass Energy Platform that will establish the nation’s first microgrid utility.

“This initiative addresses a significant problem by providing resilient energy solutions for this county and opens up tremendous opportunities for our company to meet similar needs across North America,” Correlate Energy CEO Todd Michaels stated (https://ibn.fm/YSuJd).

Microgrids are self-sufficient energy systems that serve discrete geographic footprints, which have generally been well-funded sites such as college campuses or hospital complexes that aren’t just using solar panels for their reduced carbon footprints, but as part of systems that keep the power flowing when the larger central grid fails. Their use has expanded to business centers and some neighborhoods (https://ibn.fm/XFOO9).

The landmark initiative by Distributed Energy Capital and Compass Energy Platform to adopt renewable utility infrastructure is for Ohio’s Cuyahoga County. The county formed Cuyahoga Green Energy (“CGE”) three years ago as a utility focused entirely on renewable energy and resiliency (https://ibn.fm/Xxrkj).

CGE’s project differs from traditional microgrids in that it will provide power to multiple interconnected customers, including commercial, industrial, and later, government and community loads, according to Correlate.

The county issued a 10-year contract for the utility’s operations that employs Compass Energy to manage the utility’s technical standards, customer billing and project financing. Distributed Energy Capital, operated by Correlate, will provide financial and technical development services that support the partnership by structuring near and long-term project financing, according to the company.

Cuyahoga anticipates key development milestones by next year that will help support economic growth in the Cleveland metro region.

The teams involved with the utility are discussing similar microgrid partnership models with other municipalities, demonstrating the scalable potential of the model for addressing climate change through community-level renewable energy solutions.

For more information, visit the company’s website at www.Correlate.Energy.

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The U.S. robot as-a-service market was valued at $440 million in 2023, project with substantial growth to reach $2.19 billion by 2033 with a robust Compound Annual Growth Rate of 17.59% from 2024 to 2033 from Precedence Research
• Nightfood Holdings has launched a new subsidiary, Future Hospitality Ventures, to capitalize on this explosive growth while solving employment problems in the hospitality industry
• Future Hospitality Ventures has RaaS (robots-as-a-service) offerings that improve operational efficiencies for both front and back of house
• The company has been demonstrating its RaaS technology to restaurants, health care facilities, hotels, and even school operators with great interest

Nighttime snacking is a $50+ billion market. The global robotic as-a-service market size was valued at $440 million in 2023, with a CAGR of 17.59% from 2024 to 2033, forecasted by Precedence Research.

Nightfood Holdings (OTCQB: NGTF), a company focused on acquisitions in the hospitality, food service, and CPG sectors, isn’t just about satisfying late-night cravings, they have a vision to disturb entire industries. Their innovative approach extends beyond cookies, venturing into the realm of hospitality with a new groundbreaking subsidiary, Future Hospitality Ventures, that management believes can help solve the hospitality employment crisis.

This diversification creates a unique opportunity for investors seeking exposure to a variety of high-growth sectors. With a focus on their cutting-edge automation solutions, Nightfood offers a chance to invest in the future of food and hospitality.

The Hospitality Labor Crisis: A Burning Platform for Innovation

While Nightfood leads the charge in the nighttime snack revolution towards healthier munchies, the launch of Future Hospitality tackles a critical challenge plaguing the hospitality industry: a crippling labor shortage. According to the American Hotel & Lodging Association (“AHLA”), more than two thirds of hotels continue to experience staffing shortages, now offering more pay and a host of incentives in order to attract and retain talent.

It’s a ubiquitous problem, evidenced by news headlines filled with stories of the hospitality industry in turmoil. California’s soaring minimum wage of $20 per hour has forced closures of long-standing businesses, leaving others scrambling for solutions. Future Hospitality offers a revolutionary answer: automation through robots-as-a-service (“RaaS”).

Future Hospitality: Automation Takes Center Stage

Future Hospitality’s plug-and-play robotic solutions are designed to streamline operations and enhance both guest experiences and staff efficiency. Their offerings cater to both front-of-house and back-of-house needs:

• Front-End Revolution: Advanced serving robots work alongside wait staff, ensuring faster, more reliable service. These robots minimize wait times, reduce errors, and free up staff to focus on guest interaction
• Back-End Boost: Smart cooking bots transform kitchens. These intelligent assistants deliver consistent food quality, allowing even inexperienced staff to prepare delicious meals quickly, addressing bottlenecks in busy kitchens

Future Hospitality: Demonstrating Innovation, Sparking Interest

Future Hospitality has been actively showcasing their robotic solutions to a broad audience, such as regional restaurant franchises, assisted living facilities, hotels, and even hospital operators. These demonstrations have garnered significant interest from industry leaders seeking solutions to optimize operations and answer labor shortages, service inconsistencies, and surging staffing costs, amongst other benefits.

“We are excited about the positive feedback from potential partners who recognize the value our robotics solutions bring to their operations,” said Lei Sonny Wang, CEO of Nightfood Holdings in a press release on the progress. “Our technologies not only improve operational efficiencies but also enhance the overall customer experience, which is crucial in today’s competitive market,” he concluded.

Nightfood: A Sweet Dream for Investors and the Future of Hospitality

Nightfood Holdings offers a compelling proposition for both consumers and investors. For consumers, they provide sleep-friendly snacks and a hospitality experience enhanced by innovation. For investors, NGTF presents an opportunity to capitalize on multiple rapidly growing markets – nighttime snacks and hospitality automation – with a company at the forefront of both.

For more information, visit the company’s website at https://nightfood.com/.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• SenesTech, a rapidly growing provider of proven rodent fertility control products, is looking to address the growing rodent problem with its unique control solutions
• These rodent fertility control solutions have been tried and tested out in the field with positive results, with the active ingredient in its flagship product scientifically proven to reduce rodent fertility without the use of poisons and traps
• Their products are unique in offering a viable and sustainable solution, especially with studies having shown that climate change brings with it longer stretches of warmer weather, hence more time for rodent breeding

In the fiscal year 2023, calls to 3-1-1 in Washington D.C. regarding rat sightings and complaints hit 16,391, up from 8,107 in 2020 (https://ibn.fm/0j62f). For the state government, the hotline was set up as a means to deal with the growing rat problem, which did help deal with the situation, but only to a certain extent. Similar efforts to curb the rat infestation problem were translated to other cities across the country, with New York declaring the rodents as “public enemy No. 1” and targeting rat mitigation zones in neighborhoods with historically high rat activity (https://ibn.fm/tJ4Gx).

Despite these efforts and stances, progress in mitigating the problem has until now been minimal. The primary method to address it has been poisoning the rats, which is unsustainable and potentially harmful to other animals as well as humans. SenesTech (NASDAQ: SNES), a rodent fertility control product provider, and the inventor of the only EPA-registered contraceptive for male and female rats, is successfully addressing the situation by offering a sustainable, safe, and cost-effective solution to the rat problem. Its solutions have been tried and tested in the field and shown to work. The active ingredient in its flagship product, Evolve, is scientifically proven to reduce rodent fertility.

Studies have shown that with climate change, there have been longer stretches of warmer weather. For rodents, this means more time for breeding, resulting in a spike in rodent population within a short time. This has been the case in a recent new coverage by ABC 7 News, where reports of a spike in rat population in Washington DC was linked to temperature rises (https://ibn.fm/EPTeB). It has brought with it billions of dollars in damages annually, in addition to diseases that can be harmful, if not deadly, to other animals and humans. Moreover, the rat population is increasing with the growing human population.

“We’re piled up on top of each other. And so as the people increase, the density increases, the refuse increases, and our cities get older and older, we end up with these [rat] populations that are reflecting our increases in our density,” noted Bobby Corrigan, a renowned rodentologist.

To address the problem, DC’s leadership has adopted anti-rat trash cans and recycling bins named “Bigbelly.” This is in a move to deprive rats of food, potentially starving them to death and reducing their population. While it is seen as a step in the right direction, it is not as sustainable, especially in the long run. On the other hand, cities’ adoption of poisoning these rats has also proven to be unsustainable, and the push for non-lethal rodent control methods has further accentuated the benefits and overall value of SenesTech’s offering.

SenesTech understands all of these standard method shortcomings and is addressing them using its increasingly popular rodent fertility control products. So far, it has been proven that putting an entire population of rats on birth control could see close to a complete elimination of that population in 12 to 18 months.

“We can’t poison our way out of the rat problem, but we can certainly do a lot of damage trying,” noted Shaun Abreu, an Upper West Side City Council Member (https://ibn.fm/umgv9).

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• D-Wave announced an extension of its partnership with Aramco to address geophysical optimization challenges using D-Wave’s quantum technology
• Over the past two years, the Aramco Research Center has utilized D-Wave’s cutting-edge quantum technologies to solve intricate optimization problems related to seismic imaging
• D-Wave announced the launch of a new hybrid quantum solver for nonlinear programs, designed to tackle increasingly complex real-world problems at its Qubits 2024 user conference

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, has announced an extension of its partnership with Aramco, a global leader in energy and chemicals, to address geophysical optimization challenges using quantum technology.

Located in Delft, Netherlands, the Aramco Research Center (the “Center”) is dedicated to advancing computing technologies to tackle global energy issues. Over the past two years, the center has utilized D-Wave’s cutting-edge quantum technologies to solve intricate optimization problems related to seismic imaging—a sophisticated technique akin to ultrasound, employed to map geological layers several kilometers beneath the surface.

With the assistance of D-Wave, the Center has successfully generated its initial subsurface maps by processing tens of gigabytes of seismic data. Its goal for 2024 is to utilize D-Wave quantum technologies to process a terabyte of seismic data. Leveraging D-Wave’s quantum computers and hybrid solvers via the Leap™ quantum cloud service, Aramco’s research team has developed hybrid classical-quantum geophysical applications. These advancements have resulted in notable performance improvements over classical computing methods in terms of solution time and scalability.

“I’m excited to see how far we’ve been able to push quantum technologies to tackle such a large optimization problem as subsurface imaging,” said Marcin Dukalski, Quantum Applications Lead at the Center (https://ibn.fm/YSxgR). “We look forward to expanding our work with D-Wave, which will be centered on reaping even greater tangible benefits from the Advantage2™ system.”

Dr. Trevor Lanting, D-Wave’s Chief Development Officer, said that together with Aramco, D-Wave is demonstrating its quantum technology’s ability to take on core data challenges in geophysical research. “We look forward to helping Aramco researchers maximize quantum’s positive impact on their computational challenges as they look to turn data into usable knowledge of the subsurface.”

At its recent global Qubits 2024 user conference, D-Wave announced the launch of a new hybrid quantum solver for nonlinear programs, designed to tackle increasingly complex real-world problems. This new solver, now accessible via D-Wave’s Leap quantum cloud service, is expected to enhance customers’ ability to solve large-scale optimization problems, surpassing the capabilities of existing technologies.

The new hybrid solver supports up to two million variables and constraints, marking a tenfold increase in problem size capacity compared to previous D-Wave solvers for certain applications, as indicated by preliminary benchmarking studies. This solver is part of D-Wave’s expanding portfolio of commercial quantum optimization solutions, aligning with the company’s ambitious go-to-market (“GTM”) growth strategy announced earlier this year. D-Wave’s solutions, which encompass hardware, software, and professional services, aim to substantially improve time-to-solution for organizations seeking to optimize their operational processes and performance.

Real-world problems, such as production scheduling, involve complex interactions between multiple variables. D-Wave’s new solver is particularly adept at managing nonlinear relationships, offering an advantage over solvers restricted to linear relationships. Its user-friendly interface simplifies the conversion of real-world problems into hybrid quantum problem-solving approaches, offering flexibility and accuracy across various applications:

• Optimized workforce scheduling: Industries with large hourly workforces or 24/7 operations can streamline staffing processes, enhance productivity, and reduce costs, while ensuring compliance with labor laws and employee availability and preferences.
• Enhanced production scheduling: Manufacturers can optimize task sequences in assembly lines to minimize completion times and maximize throughput, considering factors such as machine availability, processing times, and due dates to better meet customer demands.
• Efficient and sustainable logistics routing: Commercial trucking fleets and tour operators can optimize routes to reduce drive time, manage fuel consumption, and address carbon emissions, thereby lowering costs and improving fleet utilization. Preliminary internal studies show that the new hybrid quantum solver can find feasible routes for up to ten times more cities than previous solutions in scenarios like the Traveling Salesperson Problem, the challenge of finding the shortest route around a list of destinations.

“We are confident that this solver will simplify and accelerate customers’ journey to successful quantum technology adoption, helping them more quickly drive return-on-investment, and gain a competitive edge,” said Dr. Alan Baratz, CEO of D-Wave (https://ibn.fm/ykttN). “Many organizations are recognizing that their most complex computational problems go well beyond the capabilities of existing solutions. They’re adopting hybrid quantum solutions to find better answers to transform operations faster and improve the bottom line.”

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond company management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of its Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

DGE invites leaders, executives and professionals from the biotech, pharma, and medical device sectors, to attend the 5th Clinical Trials Agreements Conference being held August 21-22, 2024, in Philadelphia. The conference focuses on discussions such as accelerating negotiations, AI advancements, fair market value, and building a modern day clinical site budget.

The event is hosted by Dynamic Global Events (“DGE”), a global leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the pharma, biotech, medical devices, and all healthcare industries.

Clinical Trial Agreements rely on effective communication among sponsors, CROs, and the research institution. Key topics that will be covered include enhancing communication transparency, evaluating the impact of CROs on negotiation timelines, and highlighting site forms and institution policies in CTAs.

Featured topics covered include:

• Apply Key Lessons from Decentralized and Remote Clinical Trials 
• Evaluate the Impact of CROs on Negotiation Timelines 
• Fast-Track Your CTA Negotiations: Key Factors and Best practices 
• Examine the Recent FDA Guidance Surrounding Digital Health Technologies 
• Revolutionize Contract Review Processes by Harnessing AI to Enhance Operational Efficiency 
• Map out CTAs in a Global Landscape 
• Build a Modern – Day Clinical Site Budget: Hybrid Studies, DCT, and Naïve Sites

In addition, attendees can learn the intricacies of CTA negotiations from industry experts through audience Q&A as well as networking breaks. We hope to see you there!

To know more, please visit https://ibn.fm/Bjrxt.

The 4th PRC Performance Optimization Summit, held on June 5-6, 2024, in Philadelphia, gathered industry leaders to discuss optimizing promotional review committees (“PRC”). The summit featured sessions on compliance strategies, incorporating AI in PRC operations, and managing content updates for various digital platforms. Attendees benefited from expert presentations, interactive workshops, and networking opportunities aimed at enhancing PRC effectiveness and teamwork. Key discussions included ensuring compliance, preparing for modular content updates, and shaping review strategies for emerging technologies like virtual reality and mobile applications.

The summit provided a comprehensive overview of best practices for promotional review processes, focusing on real-world applications and practical solutions for common challenges faced by PRCs. Speakers joined from organizations including AbbVie, Biogen, Moderna, and Otsuka.

For those unable to attend in person, the summit offers an On-Demand option, allowing participants to watch the conference sessions at their convenience from anywhere. This ensures broader accessibility and the opportunity to benefit from the insights shared during the event.

Watch On-Demand: https://dgevents.com/event/prc-performance_optimization-summit/

• Clene revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado
• The only current FDA-approved drug for Rett Syndrome is trofinetide, approved in 2023
• CNM-Au8 treatment showed improvements in mitochondrial respiration deficits in Rett patient-derived astrocytes

Clene (NASDAQ: CLNN), along with its subsidiary Clene Nanomedicine Inc., a biopharmaceutical company specializing in mitochondrial health to address neurological diseases like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment. The data was presented by Dr. Karen Ho, Clene’s Vice President of Translational Medicine, at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado. The presentation, titled “CNM-Au8, a Candidate First-in-Class Nanotherapeutic for Treatment of Rett Syndrome,” highlighted CNM-Au8’s potential (https://ibn.fm/NAtz7).

Rett Syndrome is a severe and rare pediatric neurological disorder caused by mutations in the MECP2 gene on the X chromosome. It predominantly affects females, occurring in about 1 in 10,000 live female births. Children with MECP2 mutations develop normally for the first six months of life but then experience a regression in skills, leading to various neurological and developmental issues such as loss of hand movement, abnormal gait, respiratory problems, autism spectrum traits, motor dysfunction, loss of verbal skills, seizures, and Parkinson-like features. The disorder also involves microcephaly and myelin loss in the brain. Currently, the only FDA-approved drug for Rett Syndrome is trofinetide, approved in 2023.

CNM-Au8 is an oral nanotherapeutic that enhances energy metabolism in nervous system cells, including neurons and oligodendrocytes, to support neuronal survival and remyelination. Clene has primarily been developing CNM-Au8 for ALS and MS, but its unique mechanism of action has led to considering its potential for treating Rett Syndrome.

The research, conducted in collaboration with Dr. Kathrin Meyer, formerly of Nationwide Children’s Hospital and now Chief Scientific Officer of Alcyone Therapeutics, along with her former postdoctoral researchers Drs. Meysam Ganjibakhsh and Andrea Sierra Delgado, explored the impact of CNM-Au8 on Rett Syndrome. Dr. Delgado is now a Research Assistant Professor at the University of Missouri.

Key preliminary findings include significant improvements in neuronal health (p<0.01), neuron survival (p<0.0001), and neurite lengths (p<0.05) in an in vitro model of Rett Syndrome.

Additionally, CNM-Au8 treatment showed improvements in mitochondrial respiration deficits in Rett patient-derived astrocytes, with full rescue (p<0.0001) of both basal and ATP-linked respiration in one Rett line and partial rescue (p<0.001 improvement in ATP-linked respiration) in another.

Dr. Ho said Rett Syndrome has a disease mechanism that shares some common features with both ALS and MS, with dysfunctional energy metabolism, glutamate excitotoxicity, demyelination, and mitochondrial dysfunction being hallmarks of the challenges faced by the nervous system in all three of these diseases.

“These preliminary data suggest that CNM-Au8 may treat Rett syndrome by potential rescue of mitochondrial dysfunction, thereby promoting neuronal health, survival, and synaptic structure. If CNM-Au8 proves to be a successful treatment for Rett syndrome, this will add further affirmation to Clene’s central thesis: that CNM-Au8—with its versatile and unique catalytic mechanism—holds promise as a potential treatment for multiple diseases of the nervous system, beyond its current targets of ALS and MS,” Dr. Ho added.

The study received support from the Baby Eleanor Foundation, and the team acknowledged the donation of Rett and healthy control cells from anonymous individuals. Dr. Ho emphasized the potential impact of CNM-Au8 on millions of people with difficult-to-treat neurological diseases, highlighting the rewarding nature of their ongoing research. “It’s a truly rewarding time to participate in the development of CNM-Au8, which has strong potential to make a difference to the millions of people living with difficult-to-treat neurologic diseases,” she said.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN